Grant: Idea to Innovation
McMaster University
$14,831.00
Market assessment: genome-based analytics for antimicrobial resistance prediction
EF 2015-16
Résumé
Antimicrobial resistance (AMR) is among the most pressing public health crises of the 21st Century. Despite the importance of resistance to health, this field has been slow to take advantage of genome scale tools. Rather, phenotype based criteria dominate the epidemiology of antibiotic action and effectiveness. As a result, there is a poor understanding of which antibiotic resistance genes are in circulation in Canada and internationally, which ones are a threat, and how clinicians and public health workers can manage the crisis of resistance. However, DNA sequencing is rapidly decreasing in cost and as such we are on the cusp of an age of high-throughput molecular epidemiology. What are needed are tools for rapid, accurate analysis of DNA sequence data for the genetic underpinnings of antibiotic resistance. Our research focuses on development of databases and software in preparation for a world where DNA sequencing of AMR pathogens has become commonplace at every hospital, clinic, and outbreak. Driven by advances in DNA sequencing technology and the increasing use of pathogen genome sequencing, our data and software enable high-throughput AMR research and surveillance in academic, government, and industrial settings. We develop computer algorithms to detect resistance genes, perform global surveillance of their spread, and to inform drug usage and stewardship from raw DNA sequence. We here propose to commercialize our data and algorithms for use outside of academia and request funds for a Market Assessment of genome-based analytics for antimicrobial resistance prediction which will allow us to create a product development and business plan for successful technology transfer and commercialization.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
485186-2015
Name nom
McArthur, Andrew
Department département
Biochemistry and Biomedical Sciences
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
14831
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5004
Research subject group en
Genetics
Research subject group fr
Génétique
Research subject en
Genome analysis
Research subject fr
Analyse du génome
Partie
1
Nb partie
1
Application title
Market assessment: genome-based analytics for antimicrobial resistance prediction
Keyword
NSERC
Application summary
Antimicrobial resistance (AMR) is among the most pressing public health crises of the 21st Century. Despite the importance of resistance to health, this field has been slow to take advantage of genome scale tools. Rather, phenotype based criteria dominate the epidemiology of antibiotic action and effectiveness. As a result, there is a poor understanding of which antibiotic resistance genes are in circulation in Canada and internationally, which ones are a threat, and how clinicians and public health workers can manage the crisis of resistance. However, DNA sequencing is rapidly decreasing in cost and as such we are on the cusp of an age of high-throughput molecular epidemiology. What are needed are tools for rapid, accurate analysis of DNA sequence data for the genetic underpinnings of antibiotic resistance. Our research focuses on development of databases and software in preparation for a world where DNA sequencing of AMR pathogens has become commonplace at every hospital, clinic, and outbreak. Driven by advances in DNA sequencing technology and the increasing use of pathogen genome sequencing, our data and software enable high-throughput AMR research and surveillance in academic, government, and industrial settings. We develop computer algorithms to detect resistance genes, perform global surveillance of their spread, and to inform drug usage and stewardship from raw DNA sequence. We here propose to commercialize our data and algorithms for use outside of academia and request funds for a Market Assessment of genome-based analytics for antimicrobial resistance prediction which will allow us to create a product development and business plan for successful technology transfer and commercialization.